Thus, ASCT2 and GS might represent attractive companion biomarkers for selecting GC population most likely responding to Gln-targeted therapy and further validation of these potential targets for therapy targeting molecularly defined subtypes of GC is warranted. This evidence concerns the gene SLC1A5 and gastric cancer.